<DOC>
	<DOCNO>NCT00006365</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray source damage tumor cell . Giving radiation therapy different way may kill tumor cell . PURPOSE : Phase II trial study effectiveness external-beam radiation therapy follow implanted radiation therapy treat patient prostate cancer .</brief_summary>
	<brief_title>External-Beam Radiation Therapy Plus Implanted Radiation Therapy Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine acute late grade 3-5 genitourinary ( GU ) gastrointestinal ( GI ) toxic effect external beam radiotherapy follow permanent source brachytherapy use interstitial iodine I 125 seed patient intermediate risk , clinically localize adenocarcinoma prostate . II . Determine freedom prostate specific antigen ( PSA ) failure , overall survival , disease specific survival , local and/or distant clinical relapse rate patient treated regimen . OUTLINE : This multicenter study . Patients undergo external beam radiotherapy ( EBRT ) pelvis 5 day week 5 week . Permanent source brachytherapy comprise ultrasound-guided implantation iodine I 125 seed prostate perform 2-6 week completion EBRT . Patients follow 1 , 3 , 6 , 9 , 12 month , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 110 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove locally confine adenocarcinoma prostate Clinical stage T1cT2b , NX N0 , M0 Gleason score 26 AND PSA great 10 ng/dL great 20 ng/dL OR Gleason score 7 AND PSA great 20 ng/dL Prostate volume great 60 mL transrectal ultrasound prior external beam radiotherapy American Urologic Association void symptom score great 18 No distant metastasis PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Zubrod 01 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No hip prosthesis No malignancy within past 5 year except basal cell squamous cell skin cancer No major medical psychiatric illness would preclude study Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Prior induction hormonal therapy allow start 6 month prior study Radiotherapy : See Disease Characteristics No prior radiotherapy pelvis Surgery : No prior transurethral resection prostate No radical surgery carcinoma prostate</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
</DOC>